This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Early Winners & Losers

Cytokinetics (CYTK - Get Report) retreated after the South San Francisco, Calif.-based biopharmaceutical company said an interim analysis following the first stage of a two-stage phase II clinical trial for Ispinesib, its treatment for recurrent and metastatic head-and-neck squamous-cell carcinoma, determined that the drug did not satisfy the criteria for advancement to Stage 2.

The best overall response to date in the clinical trial was disease stabilization, the company said, which was observed in five of 19 patients. Ispinesib is being developed in collaboration with GlaxoSmithKline (GSK - Get Report). Shares of Cytokinetics were trading down 52 cents, or 8.19%, to $5.83.

CKE Restaurants (CKR) gained after Standard & Poor's said the Carpinteria, Calif.-based restaurant chain will replace Ryan's Restaurant Group (RYAN) on the S&P Small-Cap 600 after the close of trading on Thursday. Ryan's is being acquired by Buffets Inc. in a deal expected to close on or about that day, Standard & Poor's said. Shares were climbing 43 cents, or 2.57%, to $17.15.

Bright Horizons Family Solutions (BFAM - Get Report) rose after Standard & Poor's said the Watertown, Mass.-based company will replace FileNet (FILE) on the S&P Small-Cap 600 after the close of trading on a date to be announced. FileNet is being acquired by IBM (IBM) in a deal awaiting final approval. Shares were climbing 77 cents, or 1.91%, to $41.06.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NAVR $0.00 0.00%
ACTL $0.00 0.00%
BFAM $65.30 0.00%
CYTK $8.40 0.00%
GSK $43.14 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs